Patents Assigned to Santen Pharmaceutical Co. Ltd.
  • Patent number: 9827139
    Abstract: An intraocular lens injector includes a lens holder holding an intraocular lens which has an optic and a haptic extending in a curved shape from the optic, a plunger which comes into contact with the intraocular lens and pushes out the intraocular lens, and a device body in which the plunger is inserted projectably/retractably and in which the lens holder can be attached in an intersecting direction relative to an axis of the plunger. The lens holder includes a position regulating portion for regulating a disposing position of the haptic in such a manner that a distal end of the plunger at an initial position before the plunger is pushed in and the optic may be laid on a common plane with a portion of the haptic lying on top of the plunger.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: November 28, 2017
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Christian Winfried Wagner, Yoshitaka Yamada, Katsuyuki Ueno
  • Publication number: 20170312174
    Abstract: Provided is an eye drop container having superior identifying power. The eye drop container includes an identifying indicium including a shape, a pattern, a color or combination thereof imparted to a lateral face of a container body, and a further identifying indicium identical or similar to the identifying indicium imparted to a lateral face of a cap part which is detachably attached to a dispensing mouth of the container body, the indicia making it possible to identify the unity of the container body and the cap part. The container is packaged by a sealing label that renders these identifying indicia visible when the cap part is attached to the container body.
    Type: Application
    Filed: October 20, 2015
    Publication date: November 2, 2017
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventor: Yoshiyuki Azuma
  • Publication number: 20170266109
    Abstract: Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.
    Type: Application
    Filed: June 1, 2017
    Publication date: September 21, 2017
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Sreenivasu MUDUMBA, Philippe JM DOR, Thierry NIVAGGIOLI, David A. WEBER, Sidiq FAROOQ
  • Publication number: 20170247342
    Abstract: An object is to provide a novel production method suitable for industrial production of a 3,3-dimethyl-3,4-dihydro-1H-quinoxalin-2-one derivative and a synthetic intermediate for the method.
    Type: Application
    Filed: May 12, 2017
    Publication date: August 31, 2017
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kazuhiro KUDOU, Masato NAGATSUKA
  • Publication number: 20170202845
    Abstract: Provided is a prophylactic or therapeutic agent for a posterior ocular disease, which comprises a compound represented by formula (1) below: its enantiomer or diastereomer, or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Application
    Filed: July 17, 2015
    Publication date: July 20, 2017
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventor: Atsushi YOSHIDA
  • Publication number: 20170182085
    Abstract: Provided are a therapeutic agent and a prophylactic agent for keratoconjunctive disorder, each agent comprising sacran. A therapeutic agent or a prophylactic agent for keratoconjunctive disorder, each agent comprising sacran.
    Type: Application
    Filed: July 13, 2015
    Publication date: June 29, 2017
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Shinichiro KANEKO, Masaaki SASAOKA, Takashi NAGANO, Satoshi SHIRAE
  • Patent number: 9676703
    Abstract: An object is to provide a novel production method suitable for industrial production of a 3,3-dimethyl-3,4-dihydro-1H-quinoxalin-2-one derivative and a synthetic intermediate for the method.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: June 13, 2017
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kazuhiro Kudou, Masato Nagatsuka
  • Patent number: 9669988
    Abstract: A fixed amount discharge container includes: a syringe barrel 3; and a piston 8 inserted in the syringe barrel 3 so as to be movable in a longitudinal direction, thereby defining a fluid chamber between the syringe barrel 3 and the piston 8. One of the syringe barrel 3 and the piston 8 includes a guide 3c that is extended in a longitudinal direction. The other of the syringe barrel 3 and the piston 8 includes a slider 9 that is movable in the guide 3c along with the other of the syringe barrel 3 and the piston 8. The guide 3c is provided with a target position contact portion 3j which the slider 9 contacts when an amount of the fluid chamber is equal to a target amount.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: June 6, 2017
    Assignee: Santen Pharmaceutical Co., LTD.
    Inventors: Takashi Kojima, Nobuo Yokouchi, Naoki Kato, Kenji Kaitsuka, Takeshi Iida
  • Publication number: 20170081286
    Abstract: In the course of developing 2-[[[2-[(hydroxyacetyl) amino]-4-pyridinyl] methyl] thio]-N-[4-(trifluoromethoxy) phenyl]-3-pyridinecarboxamide (compound A), there are the multiple problems: 1) compound A or its salt is difficult to be recrystallized, the storage stability largely differs depending on the kind of the salt, and it is very difficult to obtain a salt of compound A having excellent storage stability; 2) in a crystallization process of compound A, it is very difficult to control a crystal polymorph, and 3) compound A (free body) causes mineral deposition in the stomach when it is orally administered repeatedly.
    Type: Application
    Filed: December 2, 2016
    Publication date: March 23, 2017
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Masashi NIWA, Hiroshi DEGUCHI
  • Patent number: 9579309
    Abstract: The present invention relates to a prophylactic or therapeutic agent for a posterior ocular disease containing the compound represented by a formula (1), its enantiomer or diastereomer, or their pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: February 28, 2017
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Atsushi Yoshida, Sae Akao, Shinji Yoneda, Komei Okabe, Tomomi Kohara
  • Publication number: 20170049786
    Abstract: Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are ophthalmic formulations that deliver a variety of therapeutic agents, including but not limited to rapamycin (sirolimus), analogs thereof (rapalogs) or other mTOR inhibitors, to a subject for an extended period of time. The ophthalmic formulations may be placed in an aqueous medium of a subject, including but not limited to intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer a therapeutic agent to treat or prevent age-related macular degeneration, macular edema, diabetic retinopathy, uveitis, dry eye, or a hyperpermeability disease in a subject.
    Type: Application
    Filed: September 1, 2016
    Publication date: February 23, 2017
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Thierry NIVAGGIOLI, David A. WEBER, Philippe JM DOR, Philip REILLY
  • Publication number: 20170020809
    Abstract: Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; liquid formulations comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration in a subject.
    Type: Application
    Filed: June 15, 2016
    Publication date: January 26, 2017
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Sreenivasu MUDUMBA, Philippe JM DOR, Thierry NIVAGGIOLI, David A. WEBER, Sidiq FAROOQ
  • Publication number: 20170020910
    Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
    Type: Application
    Filed: October 10, 2016
    Publication date: January 26, 2017
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Akiko SAKATANI, Tatsuo IKEI, Koji INAGAKI, Masatsugu NAKAMURA, Kazuhiro HOSOI, Mikiko SAITO, Masaki SONODA, Yoko FUKUI, Mitsuaki KUWANO
  • Patent number: 9546140
    Abstract: In the course of developing 2-[[[2-[(hydroxyacetyl) amino]-4-pyridinyl] methyl] thio]-N-[4-(trifluoromethoxy) phenyl]-3-pyridinecarboxamide (compound A), there are the multiple problems: 1) compound A or its salt is difficult to be recrystallized, the storage stability largely differs depending on the kind of the salt, and it is very difficult to obtain a salt of compound A having excellent storage stability; 2) in a crystallization process of compound A, it is very difficult to control a crystal polymorph, and 3) compound A (free body) causes mineral deposition in the stomach when it is orally administered repeatedly.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: January 17, 2017
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Masashi Niwa, Hiroshi Deguchi
  • Patent number: 9539204
    Abstract: The objective of the present invention is to provide a new medicinal use of clarithromycin. The present invention is a therapeutic agent or a preventive agent for meibomian gland dysfunction or meibomian gland blockage and comprises clarithromycin as an active ingredient. The dosage form is preferably an eye drop or eye ointment.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: January 10, 2017
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kazutaka Kido, Takashi Nagano
  • Patent number: 9539138
    Abstract: A method of micro-incision ophthalmic surgery, comprising, in the order mentioned, the steps of: (1) injecting a first viscoelastic substance through an incision site which is lateral to corneal into an anterior chamber which is in an opposite part of the incision site with discharging aqueous humor; (2) injecting a second viscoelastic substance having higher surface tension than that of the first viscoelastic substance through the incision site into the remaining anterior chamber unfilled with the first viscoelastic substance; and (3) injecting a third viscoelastic substance having lower surface tension than that of the second viscoelastic substance through the incision site into an area of the anterior chamber which is filled with the first viscoelastic substance until the incision site is sealed with the already injected the second viscoelastic substance.
    Type: Grant
    Filed: January 29, 2009
    Date of Patent: January 10, 2017
    Assignees: SEIKAGAKU CORPORATION, SANTEN PHARMACEUTICAL CO., LTD.
    Inventor: Takao Tanaka
  • Publication number: 20160324838
    Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate, or a salt thereof. The pharmaceutical preparation has an excellent intraocular pressure lowering effect and may be used as a therapeutic or preventive agent for glaucoma or ocular hypertension or an intraocular pressure lowering agent.
    Type: Application
    Filed: July 18, 2016
    Publication date: November 10, 2016
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Naveed SHAMS, Henk-Andre KROON, Hisashi KAWATA, Noriko KAWABATA
  • Publication number: 20160303093
    Abstract: Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.
    Type: Application
    Filed: June 29, 2016
    Publication date: October 20, 2016
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Sreenivasu MUDUMBA, Philippe JM DOR, Thierry NIVAGGIOLI, David A. WEBER, Sidiq FAROOQ
  • Patent number: 9452156
    Abstract: Described herein are formulations and methods for treating, inhibiting, preventing, delaying onset, or causing regression of a disease or condition relating to vascular permeability.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: September 27, 2016
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: David M. Kleinman, Thierry Nivaggioli, Mary E. Gerritsen, David A. Weber
  • Patent number: D790707
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: June 27, 2017
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Anand Doraiswamy, Jensen Buck, Daniel Hamilton